Avalo Therapeutics (AVTX) Long-Term Debt Issuances (2014 - 2023)
Avalo Therapeutics (AVTX) posted Long-Term Debt Issuances of $6.0 million for Q2 2023, up 140.52% on a QoQ basis from -$14.8 million in Q4 2022, and down 60.0% year-over-year from $15.0 million in Q2 2022.
Avalo Therapeutics (AVTX) Long-Term Debt Issuances (2014 - 2023) Analysis & Trends
Avalo Therapeutics' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $6.0 million for Q2 2023.
- Quarterly Long-Term Debt Issuances fell 60.0% year-over-year to $6.0 million in Q2 2023, while the trailing twelve-month figure through Dec 2024 was $6.0 million (down 3.13% YoY) and the FY2023 annual result came in at $21.2 million, changed N/A from the prior year.
- Long-Term Debt Issuances was $6.0 million for Q2 2023 at Avalo Therapeutics, up from -$14.8 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $15.0 million in Q2 2022 and bottomed at -$14.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 6.00 Mn |
| Dec 31, 2022 | -14.81 Mn |
| Dec 31, 2022 | -14.81 Mn |
| Jun 30, 2022 | 15.00 Mn |
| Jun 30, 2022 | 15.00 Mn |
| Dec 31, 2014 | 5.14 Mn |
| Dec 31, 2014 | 5.14 Mn |